The goal of this study is to learn if mesenchymal stem cell therapy (treatment group) can effectively treat autoimmune diseases, when compared to normal saline (given to placebo group). The primary outcome measures will be clinical improvement based on the respective disease specific clinical scores, normalization of T-lymphocyte subsets and \> 50% reduction in disease specific antibody titres. The study will also document the type and frequency of any adverse event or side effects, reported by or seen in any of the trial participants. Patients in treatment group will receive single session of MSC therapy and placebo group will receive 0.9% saline solution. The participants will be followed at 3 and 6 months.
Age range
18 Years – 50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for RA
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for Systemic lupus erythematosus
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for systemic sclerosis
Timeframe: Day 0, Weeks 12, 24, 48
Primary Outcome Measures for systemic sclerosis
Timeframe: Day 0, Weeks 12, 24, 48
Primary outcome measures in ankylosing spondlitis
Timeframe: Week 16
Primary Outcome Measure for dermatomyositis
Timeframe: Day 0, Weeks 12, 24, 48